Affiliation:
1. Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2. West China Hospital/West China school of Medicine, Sichuan University, Chengdu, Sichuan, China
Abstract
Background:
Maintaining the exposure of tacrolimus (Tac) after kidney transplantation (KT) must be
necessary to prevent acute rejection (AR) and improve graft survival,but there is still no clear consensus on the
optimal Tac target blood concentration and concentration-effect relationship is poorly defined.
Methods:
We conducted a dose-response meta-analysis to quantitatively assess the association between Tac
blood concentration and (AR) or adverse effects after KT. A comprehensive search of PubMed, Embase and
Cochrane library databases was conducted to find eligible studies up to 10th September 2018. Unpublished data
from patients receiving KT in West China Hospital (Sichuan University, China) were also collected. Both twostage
dose-response and one-stage dose-response meta-analysis models were used to improve the statistical
power.
Results:
A total of 4967 individuals from 10 original studies and 1453 individuals from West China Hospital
were eligible for the ultimate analysis. In the two-stage dose-response meta-analysis model, we observed a significant
non-linear relationship between Tac blood concentration and AR (P < 0.001) with moderate heterogeneity
(I2 = 46.0%, P = 0.08). Tac blood concentration at 8ng/ml was associated with the lowest risk of AR (RR:
0.26, 95%CI: 0.13 - 0.54) by reference to 2ng/ml. Tac concentration at 7.0 - 11.0 ng/ml reduced the risk of AR by
at least 70%, 5-14 ng/ml by at least 60%, and 4.5 – 14 ng/ml at least 50%. In the one-stage dose-response model,
we also found a strong non-linear relationship between Tac and AR (P < 0.001) with moderate heterogeneity (I2 =
41.2%, P = 0.10). Tac concentration of 7.5 ng/ml was associated with the lowest risk of AR (RR: 0.35, 95%CI:
0.16 - 0.77). The blood concentration at 5.5 - 9.5 ng/ml was associated with the reduced AR by at least 60% and
4.5 - 10.5 ng/ml by at least 50% by reference to 2 ng/ml.
Conclusion:
Maintaining Tac blood concentration at 5 - 9.5 ng/ml within the first year may prevent AR most
effectively.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献